Using economic analysis to determine the resource consequences of choices made in planning clinical trials
- 1 January 1985
- journal article
- research article
- Published by Elsevier in Journal of Chronic Diseases
- Vol. 38 (9) , 753-765
- https://doi.org/10.1016/0021-9681(85)90118-3
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Sample Size Nomograms For Interpreting Negative Clinical StudiesAnnals of Internal Medicine, 1983
- Funding More NIH Research GrantsScience, 1983
- Cost-Effective Priorities for Cancer PreventionScience, 1983
- EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1981
- Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial InfarctionNew England Journal of Medicine, 1981
- The FDA's Critique of the Anturane Reinfarction TrialNew England Journal of Medicine, 1980
- Sulfinpyrazone in the Prevention of Sudden Death after Myocardial InfarctionNew England Journal of Medicine, 1980
- The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Control TrialNew England Journal of Medicine, 1978
- Steroids in the Treatment of Clinical Septic ShockAnnals of Surgery, 1976
- Effectiveness of Betamethasone in Management of Severe InfectionsNew England Journal of Medicine, 1971